Composition with function of promoting bone health and application thereof
By combining Bifidobacter brevis i 1088 powder, calcium lactate and alkaline protein, the formed composition significantly improves calcium utilization and bone density in bone health products, solving the poor effect of existing products and The problem of limitations in applicability provides more effective osteoporosis improvement effects.
Patent Information
- Application Number
- CN202411228811.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-07
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-03
AI Technical Summary
Existing products that promote bone health have side effects, low absorption rate and limitations in applicability. Probiotics or epibiotics have weak effects and have a long time to promote bone health. The bioavailability of milk calcium is affected by a variety of factors. Low content of sex protein limits large-scale production and application.
Using a composition comprising Bifidobacter brevis i 1088 powder, lactoccal and colostrum alkaline protein, the viable amount of Bifidobacter brevis i 1088 powder or the synergistic effect of the inactivatedobacter brevis i 1088 powder with lactoccal and CBP , used to prepare products that promote bone health functions, such as formula milk powder for middle-aged and elderly people, low-temperature yogurt and room-temperature liquid milk.
It significantly improves the conversion rate of calcium converted into calcium in the bones, improves the actual utilization rate of calcium, significantly improves the bone density, bone volume fraction and trabecular thickness in the osteoporosis model, and reduces the trabecular trabecular The spacing and inactivated bacteria powder have good stability and will not produce post-acid again.
Smart Images

Figure BDA0005025478600000081
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microbial engineering and relates to a composition comprising Bifidobacterium breve I1088, in particular to a composition having the function of promoting bone health and an application thereof. Background Art
[0002] As the global population ages, bone health issues have gradually become the focus of social attention. Bone diseases, such as osteoporosis, not only affect the quality of life of the elderly, but also place a heavy burden on the healthcare system. Therefore, the development of new products and technologies that can promote bone health has important social significance and market potential. Currently, there are a variety of products and methods on the market for improving bone health, including calcium supplements, vitamin D, and specific drug therapies. However, these methods often have limitations, such as possible side effects from long-term use, low absorption rate, and limited applicability to specific populations.
[0003] Studies have shown that probiotics can regulate the balance of intestinal flora and may affect the intestinal absorption of calcium and other minerals through the gut-bone axis, thereby indirectly promoting bone health. Postbiotics refer to preparations of inanimate microorganisms and / or their components that are beneficial to the health of the host. They can also exert health benefits after the death of probiotics. In recent years, postbiotics prepared from probiotics have gradually become a new trend in products that promote bone health. However, probiotics or postbiotics have certain limitations in promoting bone health, such as weak effects and a longer time required to achieve significant effects.
[0004] Milk calcium, also known as whey calcium, is a combination of mineral salts obtained by dehydrating, defatting, and drying and spraying calcium extracted from milk. Although milk calcium has high bioavailability and easy absorption, its bioavailability in the body is also affected by factors such as dietary fiber, fat digestion, vitamin D deficiency, and inappropriate calcium-phosphorus ratio.
[0005] Colostrum basic protein (CBP) is a protein found in bovine colostrum that has the property of promoting bone growth and repair. However, the content of CBP in bovine colostrum is very low, only 0.04%, which limits its large-scale production and application. Therefore, how to efficiently utilize the function of raw materials has become the primary bottleneck of product production and nutritional health. Summary of the invention
[0006] The purpose of the present invention is to provide a composition having the function of promoting bone health and its application, so as to solve the problem that the current products promoting bone health have various disadvantages and poor calcium supplementation effect.
[0007] In order to achieve the above object, the technical solution adopted by the present invention is:
[0008] A composition with the function of promoting bone health, comprising Bifidobacterium breve I1088 bacterial powder, milk calcium and colostrum alkaline protein.
[0009] Among them, Bifidobacterium breve i 1088 (Latin name: Bifidobacterium breve), whose strain has been deposited in the General Microbiological Center of China Microbiological Culture Collection Administration Committee on May 8, 2023, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCCNO.27281. The strain has been first disclosed in the Chinese invention patent with publication number CN117143778A and the name "Bifidobacterium breve i 1088 and its application".
[0010] As a limitation, in parts by weight, the Bifidobacterium breve I 1088 powder is 0.2-1000 parts, the milk calcium is 600-2500 parts, and the colostrum alkaline protein is 40-200 parts.
[0011] As another limitation, the Bifidobacterium breve I 1088 bacterial powder includes live bacterial powder and / or inactivated bacterial powder.
[0012] As a further limitation, the live bacterial count of the Bifidobacterium breve i1088 or the live bacterial count before inactivation thereof is 3×10 8 -5×10 11 CFU / g or CFU / mL.
[0013] The present invention also provides an application of the above-mentioned composition having the function of promoting bone health, wherein the composition is used to prepare a product having the function of promoting bone health.
[0014] As a limitation, the function of promoting bone health includes preventing and / or improving osteoporosis.
[0015] The present invention also provides a formula milk powder for middle-aged and elderly people, comprising the above-mentioned composition with the function of promoting bone health.
[0016] The present invention also provides a low-temperature yogurt comprising the above composition having the function of promoting bone health.
[0017] The present invention also provides a room temperature liquid milk, comprising the above composition having the function of promoting bone health.
[0018] Due to the adoption of the above technical solution, the present invention has the following technical advances compared with the prior art:
[0019] ① The present invention provides a composition with the function of promoting bone health. Bifidobacterium breve i1088, milk calcium and CBP have a synergistic effect. While supplementing calcium, the conversion rate of calcium in the blood to calcium in the bones is increased through the action of probiotics, and the actual utilization rate of calcium is increased, which can effectively promote bone health. According to experimental data, compared with the composition of i1088 bacterial powder or milk calcium and CBP, the composition can significantly increase the bone density, bone volume fraction and trabecular thickness in the osteoporosis model of female rats, and significantly reduce the trabecular spacing in the osteoporosis model of female rats;
[0020] ② The composition provided by the present invention has the function of promoting bone health. Even if the Bifidobacterium breve I 1088 bacterial powder is inactivated bacterial powder, it can effectively improve osteoporosis. The inactivated bacterial powder has good stability and will not produce post-acid problems after fermentation. There is no need to consider the maintenance of the number of live bacteria. DETAILED DESCRIPTION
[0021] The present invention is further described in detail below by specific examples. It should be understood that the described examples are only used to explain the present invention, and are not intended to limit the present invention.
[0022] Unless otherwise specified, the experimental methods used in the following examples are conventional methods in the art.
[0023] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0024] Example 1
[0025] This embodiment provides a composition having the function of promoting bone health, wherein the composition comprises 10 g of Bifidobacterium breve i 1088 live bacteria powder, 792 g of lactic acid and 60 g of CBP, wherein the live bacteria amount of the Bifidobacterium breve i 1088 live bacteria powder is 1×10 11 CFU / g.
[0026] Example 2
[0027] This embodiment provides a middle-aged and elderly formula milk powder, wherein a composition having the function of promoting bone health is added to the milk powder (the addition amount is 5.7wt%), and the composition comprises 0.2g of Bifidobacterium breve i 1088 live bacteria powder, 600g of milk calcium and 40g of CBP, wherein the live bacteria amount of the Bifidobacterium breve i 1088 live bacteria powder is 3×10 11 CFU / g.
[0028] Example 3
[0029] This embodiment provides a low-temperature yogurt, to which a composition having a bone health promoting function is added (the addition amount is 1 wt%), the composition comprising 1 g of Bifidobacterium breve i 1088 live bacteria powder, 250 g of milk calcium and 40 g of CBP, wherein the live bacteria amount of the Bifidobacterium breve i 1088 live bacteria powder is 2×10 11 CFU / g.
[0030] Example 4
[0031] This embodiment provides a composition having the function of promoting bone health, wherein the composition comprises 10 g of inactivated bacteria powder of Bifidobacterium breve i1088, 792 g of lactic acid calcium and 60 g of CBP.
[0032] The inactivated bacteria powder of Bifidobacterium breve i 1088 is obtained by placing the i 1088 live bacteria powder in a glass or metal container with good heat conductivity, sealing it, placing it in an electric heated blast drying oven at 80° C., and heat treating it for 30 minutes.
[0033] The live bacteria amount of the Bifidobacterium breve I1088 before inactivation is 1×10 11 CFU / g, the amount of live bacteria after inactivation is less than 3000 CFU / g.
[0034] Example 5
[0035] This embodiment provides a room temperature liquid milk, to which a composition having the function of promoting bone health is added (the addition amount is 0.2wt%), the composition comprising 1000g of inactivated bacteria powder of Bifidobacterium breve i 1088, 2500g of milk calcium and 200g of CBP, wherein the amount of live bacteria of Bifidobacterium breve i 1088 before inactivation is 3x10 8 CFU / g, the amount of live bacteria after inactivation is less than 3000 CFU / g.
[0036] Example 6
[0037] The present embodiment provides a middle-aged and elderly formula milk powder, wherein a composition having the function of promoting bone health is added to the milk powder (the addition amount is 3wt%), and the composition comprises 10g of inactivated bacteria powder of Bifidobacterium breve i1088, 2000g of milk calcium and 50g of CBP, wherein the amount of live bacteria of Bifidobacterium breve i1088 before inactivation is 5x10 11 CFU / g, the amount of live bacteria after inactivation is less than 3000 CFU / g.
[0038] Example 7
[0039] This embodiment provides an application of a composition having the function of promoting bone health, wherein the composition is used to improve osteoporosis, and a control experiment is provided, which specifically includes the following steps:
[0040] S1. Preparation of experimental materials
[0041] 1) Sample preparation
[0042] Sample 1: Take the probiotic powder of Bifidobacterium breve i 1088 live bacteria and prepare it into a solution with a certain volume of physiological saline, which is recorded as active i 1088;
[0043] Sample 2: Take the probiotic powder of inactivated Bifidobacterium breve i 1088 and prepare it into a solution with the same volume of normal saline, which is recorded as inactivated i 1088;
[0044] Sample 3: The composition in Example 1 was prepared into a solution with the same volume of physiological saline, which was recorded as Complex 1;
[0045] Sample 4: The composition in Example 4 was prepared into a solution with the same volume of physiological saline, which was recorded as Complex 2;
[0046] Sample 5: 1584 g of lactic calcium and 120 g of CBP were prepared into a solution with the same volume of normal saline, which was recorded as Complex 3;
[0047] Anesthetic (5% chloral hydrate): Dissolve 5 g of chloral hydrate in about 60 ml of normal saline, add normal saline to make up to 100 ml, and store at room temperature away from light.
[0048] 2) Experimental animals
[0049] Sprague Dawley rats (SD rats), female, 10-12 weeks old.
[0050] The experimental animals were provided by Sbefor (Suzhou) Biological Co., Ltd. (China), certificate: SCXK(Su)2022-0006.
[0051] 3) Instruments, consumables and reagents
[0052] Disposable 5 ml syringe (Shanghai Kangdeli, China), electronic analytical balance Precisa12A (Plissex, Switzerland), depyrogenation ultrapure water system Millipore3150 (Millipore Corporation, USA), three-section rat gavage needle (Zhongke Life Science, China), electric constant temperature water bath HW-SY11-KP2 (Beijing Changfeng Instrument Co., Ltd., China), 1.5 ml centrifuge tube (Wuxi Nice Life Science Co., Ltd., China), ultra-low temperature refrigerator Sanyo-382AT (Sanyo Corporation, Japan), 6-0 absorbable suture (Shanghai Jinhuan Medical Instrument Co., Ltd., China), Micro-CT scanner Skyscan1276 (Bruker, USA).
[0053] 0.9% sodium chloride injection (L222042401, Sichuan Kelun Pharmaceutical Co., Ltd., China), chloral hydrate (C104202-250g, Shanghai Aladdin Biochemical Technology Co., Ltd., China), paraformaldehyde fixative (G1101, Wuhan Saiweier Biotechnology Co., Ltd., China), alendronate sodium (A115345-25g, Shanghai Aladdin Biochemical Technology Co., Ltd., China).
[0054] S2. Experimental methods
[0055] 1) Animal grouping and osteoporosis modeling
[0056] After 7 days of adaptive feeding, 80 SD rats were divided into 8 groups: blank group, model group, positive drug group, active i 1088 group, inactivated i 1088 group, and complex group (including complex group 1, complex group 2, and complex group 3), with 10 rats in each group.
[0057] Except for the blank group, all SD rats underwent ovariectomy: after anesthesia, the ventral skin was prepared, hair removed, and disinfected. A 2-cm incision was made in the midline of the abdomen using sterile surgical scissors to separate and expose the ovaries, and then the ovaries were removed after ligation with sutures. After the operation, the uterus was returned to the abdominal cavity, the muscles and skin were sutured layer by layer, and the wound was disinfected with iodine and placed on a heating pad for normal feeding after waking up.
[0058] The blank group underwent sham surgery: only anesthesia was performed to make the incision, and the ovaries were exposed but not ligated and removed. The ovaries were placed back into the abdominal cavity and the wounds were sutured. The mice were fed normally after waking up.
[0059] 2) Sample administration by intragastric gavage
[0060] The SD rats in each group were gavaged daily starting the day after surgery. The SD rats in the blank group and the model group were given a certain volume of normal saline daily; the SD rats in the positive drug group were given the same volume of 40 mg / kg alendronate sodium (solvent was normal saline) daily, once a day for 28 consecutive days.
[0061] The SD rats in the Active i 1088 group were intragastrically administered with an equal volume of Active i 1088 daily (the amount of live bacteria ingested by the rats was 1.135 x 10 8 CFU, the dosage is converted to human body, which is 5x10 per day 9 CFU), once a day for 28 consecutive days.
[0062] The SD rats in the inactivated i 1088 group were given an equal volume of inactivated i 1088 by gavage every day (the amount of inactivated bacteria ingested by the rats was 1.135 x 10 8 CFU, the dosage is converted to human body, which is 5x10 per day 9CFU), once a day for 28 consecutive days.
[0063] The SD rats in the complex group were given equal volumes of complex 1 and complex 2 by gavage every day (the daily intake of milk calcium, colostrum basic protein and bacteria in rats was 18 mg, 1.36 mg and 2.27 x 10 7 CFU, the dosage converted to human body, the daily intake is 792mg, 60mg and 1x10 9 CFU), and complex 3 (daily intake of milk calcium and colostrum basic protein for rats were 36 mg and 2.72 mg, respectively, which are equivalent to 1584 mg and 120 mg for humans per day), once a day for 28 consecutive days.
[0064] 3) Femoral sampling and scanning
[0065] 24 hours after the last intragastric administration, the femurs of SD rats in each group were taken, the muscles and connective tissues around the femurs were removed, and the femurs were fixed and preserved in paraformaldehyde fixative.
[0066] The lower femur was taken out from the fixative, rinsed with PBS buffer for 3 times, wiped dry, and wrapped with a sealing film to obtain the lower femur sample;
[0067] Start the Skyscan1276 program of the Micro-CT scanner, initialize and preheat, open the sample chamber, put the lower femur sample along the length direction of the semi-cylindrical column of the sample chamber, raise the position of the lower femur sample with the help of foam and paper to ensure that it is at the center of the semicircle, and fix it with 3M tape, close the sample chamber door, and scan with a scanning resolution of 18 μm;
[0068] After scanning, CTvox software was used for 3D reconstruction, and the femoral morphology was exported. CTAn software was used to analyze the bone density, bone tissue volume / total tissue volume (bone volume fraction), trabecular thickness, and trabecular separation / spacing in the femoral condyle area. The results are shown in Table 1. The meanings of each data are as follows:
[0069] BMD: bone density, which reflects the condition of bones. A decrease in the index indicates osteoporosis.
[0070] BV / TV: Bone volume fraction, which reflects bone metabolism. A decrease in the index means that bone decomposition is greater than synthesis, and bone mass decreases.
[0071] Tb.Th: trabecular thickness, which reflects the morphological structure of bones. A decrease in the index indicates that the pores in the bone become larger.
[0072] Tb.Sp: Trabecular spacing, this index reflects the morphological structure of bones. An increase in the index means more pores in the bone.
[0073] S3. Experimental Results
[0074] Table 1 Experimental results
[0075]
[0076] Note: *** represents p<0.001 compared with the blank group; ## represents p<0.05 compared with the model group; ### represents p<0.001 compared with the model group; different lowercase letters indicate significant differences between the experimental groups, p<0.05.
[0077] As shown in Table 1, the probiotics prepared from the live bacteria of Bifidobacterium breve i 1088 or its inactivated bacteria have a certain degree of effect in improving osteoporosis. Specifically, compared with the model group, the live bacteria i 1088 significantly increased the bone density, bone volume fraction and trabecular thickness in the osteoporosis model of female rats, and significantly reduced the trabecular spacing in the osteoporosis model of female rats. Among them, the live bacteria agent is significantly better than the inactivated bacteria agent in improving trabecular thickness and trabecular spacing, and the two have comparable effects in improving bone volume fraction and bone density.
[0078] At the same time, it can also be seen that the compositions containing the live bacteria of Bifidobacterium breve i 1088 or its inactivated bacteria have the effect of improving osteoporosis, and the effect is better than that of the simple bacteria or the simple composition of milk calcium and CBP, indicating that Bifidobacterium breve i 1088, milk calcium and CBP have a synergistic effect in improving osteoporosis, especially the composition with live bacteria added, which has a better effect than the composition with dead bacteria added (specifically manifested in reducing the index of trabecular spacing), which is specifically manifested as follows: Compared with complex 3 and active i 1088, complex 1 has significant differences in improving bone density, bone volume fraction and trabecular thickness, and reducing trabecular spacing.
Claims
1. A composition having the function of promoting bone health, characterized in that: The composition comprises Bifidobacterium breve i1088 bacterial powder, milk calcium and colostrum alkaline protein.
2. A composition having the function of promoting bone health according to claim 1, characterized in that: In parts by weight, the powder of Bifidobacterium breve i1088 is 0.2-1000 parts, the milk calcium is 600-2500 parts, and the colostrum alkaline protein is 40-200 parts.
3. A composition having the function of promoting bone health according to claim 1 or 2, characterized in that: The Bifidobacterium breve i1088 bacterial powder includes live bacterial powder and / or inactivated bacterial powder.
4. A composition having the function of promoting bone health according to claim 3, characterized in that: The live bacterial count of Bifidobacterium breve i1088 or the live bacterial count before inactivation is 3×10 8 -5×10 11 CFU / g or CFU / mL.
5. The use of a composition having the function of promoting bone health according to any one of claims 1 to 4, characterized in that: The composition is used for preparing a product with the function of promoting bone health.
6. The use of a composition having the function of promoting bone health according to claim 5, characterized in that: The function of promoting bone health includes preventing and / or improving osteoporosis.
7. A formula milk powder for middle-aged and elderly people, characterized in that: A composition having the function of promoting bone health comprising any one of claims 1 to 4.
8. A low-temperature yogurt, characterized in that: A composition having the function of promoting bone health comprising any one of claims 1 to 4.
9. A room temperature liquid milk, characterized in that: A composition having the function of promoting bone health comprising any one of claims 1 to 4.
Citation Information
Patent Citations
Bifidobacterium breve capable of regulating skeletal development and application of bifidobacterium breve
CN116369527A
Bifidobacterium breve i1088 and application thereof
CN117143778A
Composition having bone strengthening action
JP1996165249A
Mineral absorption accelerating agent
JP1997194384A
Calcium preparation, its production, and food containing the calcium preparation
JP2000050843A
Cited By
Bifidobacterium animalis subsp. Lactis BA-C53 and application of bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health
CN121294278A
Composition for improving osteoporosis and related products and application thereof
CN121621518A
